Proteostasis Therapeutics

General Information

We are an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Leveraging our unique and comprehensive expertise of the proteostasis network, we have developed the Disease Relevant Translation, or DRT, technology platform, a validated drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this proprietary platform, we identified a new class of small molecules, which we call amplifiers, that modulate proteins in the proteostasis network.

Employees: 42
Founded: 2006
Contact Information
Address 200 Technology Square, 4th Floor, Cambridge, MA 02139, US
Phone Number (617) 225-0096
Web Address
View Prospectus: Proteostasis Therapeutics
Financial Information
Market Cap $152.9mil
Revenues $4.4 mil (last 12 months)
Net Income $-22.1 mil (last 12 months)
IPO Profile
Symbol PTI
Exchange NASDAQ
Shares (millions): 6.3
Price range $8.00 - $8.00
Est. $ Volume $50.0 mil
Manager / Joint Managers Leerink Partners/ RBC Capital Markets
CO-Managers Baird/ H.C. Wainwright & Co.
Expected To Trade: 2/11/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change